THERAPIES FOR KIDNEY DISEASE
Advanced cell and extracellular vesicles (EVs) based therapies to minimize the need for dialysis & renal transplantation in kidney disease patients.
We are aiming to prevent the progression of kidney disease thereby allowing kidney patients to live longer, better quality, and more productive lives.
PRODUCTS:
PROPRIETARY CELL-DERIVED THERAPY DELIVERY PLATFORM
CKD DISEASE AND MARKET
End Stage Kidney Disease (ESKD) is increasing rapidly worldwide as a result of aging, diabetes, hypertension, obesity, and lack of cure.
There is a pressing medical need for disruptive treatment before reaching the stage of Renal Replacement Therapy (dialysis or transplantation) by ameliorating kidney function in advanced kidney disease patients.
CKD DISEASE AND MARKET
End Stage Kidney Disease (ESKD) is increasing rapidly worldwide as a result of aging, diabetes, hypertension, obesity, and lack of cure.
There is a pressing medical need for disruptive treatment before reaching the stage of Renal Replacement Therapy (dialysis or transplantation) by ameliorating kidney function in advanced kidney disease patients.
LUPUS DISEASE AND MARKET
Lupus Nephritis is a particular severe kidney disease manifestation of Lupus, occurs in 60% of cases and correlates with a higher mortality rate. The main goal of the management of LN is to avoid Advanced Chronic Kidney Disease (ACKD).
Lupus predominantly affects women of childbearing age, with 10-fold higher prevalence in females than in males.
MANAGEMENT TEAM
Dr. Alon Yaar, DVM, MBA: Biotech Executive Leader
Dr. Masha Simanovsky, Ph.D.: R&D Leader
Dr. Shimon Amselem, Ph.D.: Formulations Leader
Avraham Hermon, MA: IP Leader
Dr Nadya Lisovoder, MD: Clinical Leader
ADVISORY BOARD
Prof. Chaim Putterman
Prof. Lilach O. Lerman
Dr. Abeer Suleiman
Prof. Gary Gilkeson
TO LEARN MORE, OR PARTNER WITH LIVEKIDNEY,
CONTACT
STRATEGIC PARTNERSHIPS
Medical University of South Carolina
Holy family hospital, Nazareth
ADVANCED CELL THERAPY
Stage: clinical stage, Phase II: 2022